UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 25, 2007 (October 24, 2007)
Commission File Number: 0-24260
Amedisys, Inc.
(Exact Name of Registrant as specified in Charter)
|
|
|
|
|
Delaware
|
|
11-3131700
|
|
(State or Other Jurisdiction
of Incorporation or Organization)
|
|
(I.R.S. Employer
Identification No.)
|
5959 S. Sherwood Forest Blvd., Baton Rouge, LA 70816
(Address of principal executive offices including zip code)
(225) 292-2031 or (800) 467-2662
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Information to be included in the
report
Section 7 — Regulation FD
|
Item 7.01.
|
Regulation FD Disclosure
|
On October 25, 2007, Amedisys, Inc.
(the “Company”) issued a press release announcing its entry into a $100 Million unsecured revolving credit facility. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company will
file a copy of the credit facility on a subsequent Current Report on Form 8-K.
In accordance with General Instruction B.2 of this Current Report on Form
8-K, the information presented herein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities
Exchange Act of 1933, as amended, except as previously set forth by specific reference in such a filing.
Section 9 — Financial Statements and
Exhibits
|
Item 9.01.
|
Financial Statements and Exhibits
|
|
|
(a)
|
Financial Statements of Business Acquired.
|
Not applicable
|
|
(b)
|
Pro Forma Financial Information.
|
Not applicable
|
|
(c)
|
Shell Company Transactions.
|
Not applicable
|
|
|
|
|
99.1
|
|
Press release dated October 25, 2007, announcing the Company’s entry into a $100 Million unsecured revolving credit facility
|
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Amedisys, Inc.
|
|
|
|
|
|
Date: October 25, 2007
|
|
By:
|
|
/s/ Dale E. Redman
|
|
|
|
|
|
Dale E. Redman
|
|
|
|
|
|
Chief Financial Officer
|
Exhibit Index
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
EX-99.1
|
|
Press release dated October 25, 2007, announcing the Company’s entry into a $100 Million unsecured revolving credit facility
|
Exhibit 99.1
|
|
|
|
|
|
|
Contact:
|
|
Amedisys, Inc.
|
|
|
|
|
|
Director of Investor Relations
|
|
Senior Vice President - Finance
|
|
|
|
Kevin LeBlanc
|
|
Thomas J. Dolan
|
|
|
|
225.292.2031
|
|
225.292.2031
|
|
|
|
kleblanc@amedisys.com
|
|
tdolan@amedisys.com
|
AMEDISYS ENTERS INTO $100 MILLION UNSECURED REVOLVING CREDIT FACILITY
BATON ROUGE, Louisiana (October 25, 2007) - Amedisys, Inc. (Nasdaq: AMED or the “Company”), one of America’s leading home health nursing companies, today
announced that it has entered into a three year $100 million unsecured revolving credit facility with a group of banks. The credit facility also includes an accordion feature, whereupon, at the Company’s election and subject to customary
conditions described in the credit agreement, the facility can be increased by up to an additional $100 million. CIBC World Markets Corp. and JP Morgan Securities, Inc. acted as joint lead arrangers.
“This new $100 million credit facility provides additional financing flexibility for the company, for general corporate purposes and to facilitate potential
acquisitions,” said William F. Borne, Chief Executive Officer of Amedisys, Inc. “While we have a strong cash position, we also have a healthy pipeline of acquisition opportunities. This credit facility improves our ability to timely
capitalize on those opportunities.”
Amedisys, Inc. is headquartered in Baton Rouge, Louisiana. Its common stock trades on the Nasdaq Global Select
Market under the symbol “AMED”.
This press release includes statements that may constitute “forward-looking” statements, usually
containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s services in the marketplace, competitive factors, changes in
government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company’s periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions or changes after the date of this release.
Additional information on
the Company can be found at:
www.amedisys.com